Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi:10.1136/gutjnl-2015-31091226818619
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl3):iii1–9. doi:10.1093/annonc/mdu203.25190710
   PubMedGoogle Scholar
• Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–237.14657227
   PubMed Web of Science ®Google Scholar
• Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale [Southern Italy Oncology Group]. J Clin Oncol. 2005;23(22):4866–4875. doi:10.1200/JCO.2005.07.11315939922
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Nagase M, Tamagawa H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016;27(8):1539–1546. doi:10.1093/annonc/mdw14127177863
   PubMed Web of Science ®Google Scholar
• Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17(10):1426–1434. doi:10.1016/S1470-2045(16)30269-827575024
   PubMed Web of Science ®Google Scholar
• Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol. 2001;28(6):551–559. doi:10.1016/S0093-7754(01)90023-511740808
   PubMed Web of Science ®Google Scholar
• Tampellini M, Sonetto C, Scagliotti GV. Novel anti-angiogenic therapeutic strategies in colorectal cancer. Expert Opin Investig Drugs. 2016;25(5):507–520. doi:10.1517/13543784.2016.1161754
   PubMed Web of Science ®Google Scholar
• Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med. 2011;32(2):88–111. doi:10.1016/j.mam.2011.04.00421565214
   PubMed Web of Science ®Google Scholar
• Millauer B, Wizigmann-Voos S, Schnürch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72(6):835–846. doi:10.1016/0092-8674(93)90573-97681362
   PubMed Web of Science ®Google Scholar
• Tarallo V, De Falco S. The vascular endothelial growth factors and receptors family: up to now the only target for anti-angiogenesis therapy. Int J Biochem Cell Biol. 2015;64:185–189. doi:10.1016/j.biocel.2015.04.00825936669
   PubMed Web of Science ®Google Scholar
• Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem. 2001;276(29):26969–26979. doi:10.1074/jbc.M10321320011350975
   PubMed Web of Science ®Google Scholar
• De Falco S, Gigante B, Persico MG. Structure and function of placental growth factor. Trends Cardiovasc Med. 2002;12(6):241–246. doi:10.1016/S1050-1738(02)00168-812242046
   PubMed Web of Science ®Google Scholar
• Bui HM, Enis D, Robciuc MR, et al. Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD. J Clin Invest. 2016;126(6):2167–2180.27159393
   PubMed Web of Science ®Google Scholar
• Nasir A, Reising LO, Nedderman DM, et al. Heterogeneity of vascular endothelial growth factor receptors 1, 2, 3 in primary human colorectal carcinoma. Anticancer Res. 2016;36(6):2683–2696.27272777
   PubMed Web of Science ®Google Scholar
• Kircher SM, Nimeiri HS, Benson AB 3rd. Targeting angiogenesis in colorectal cancer: tyrosine kinase inhibitors. Cancer J. 2016;22(3):182–189. doi:10.1097/PPO.000000000000019227341596
   PubMed Web of Science ®Google Scholar
• Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010;13(1):1–14.20012482
   PubMed Web of Science ®Google Scholar
• Sun Q, Zhou J, Zhang Z, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635–1645. doi:10.4161/15384047.2014.96408725482937
   PubMed Web of Science ®Google Scholar
• Shirley M. Fruquintinib: first global approval. Drugs. 2018;78(16):1757–1761. doi:10.1007/s40265-018-0998-z30357594
   PubMed Web of Science ®Google Scholar
• Burki TK. Fruquintinib for previously treated metastatic colorectal cancer. Lancet Oncol. 2018;19(8):e388. doi:10.1016/S1470-2045(18)30144-X29983343
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–7109.15466206
   PubMed Web of Science ®Google Scholar
• Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003;46(7):1116–1119.12646019
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60(8):2178–2189.10786682
   PubMed Web of Science ®Google Scholar
• You WK, Sennino B, Williamson CW, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011;71(14):4758–4768. doi:10.1158/0008-5472.CAN-10-252721613405
   PubMed Web of Science ®Google Scholar
• Bhide RS, Cai ZW, Zhang YZ, et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem. 2006;49(7):2143–2146. doi:10.1021/jm060059216570908
   PubMed Web of Science ®Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65(10):4389–4400. doi:10.1158/0008-5472.CAN-04-455715899831
   PubMed Web of Science ®Google Scholar
• Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006;5(4):995–1006. doi:10.1158/1535-7163.MCT-05-023516648571
   PubMed Web of Science ®Google Scholar
• Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664–671. doi:10.1002/ijc.2313117943726
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–4782.18559524
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–255.21170960
   PubMed Web of Science ®Google Scholar
• Zhou A, Zhang W, Chang C, et al. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemother Pharmacol. 2013;72(5):1043–1053. doi:10.1007/s00280-013-2282-y24043137
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14(22):7272–7283. doi:10.1158/1078-0432.CCR-08-065219010843
   PubMed Web of Science ®Google Scholar
• Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–1380.21443688
   PubMed Web of Science ®Google Scholar
• Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006;66(18):9134–9142. doi:10.1158/0008-5472.CAN-05-429016982756
   PubMed Web of Science ®Google Scholar
• Gu Y, Wang J, Li K, et al. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemother Pharmacol. 2014;74(1):95–115.24817647
   PubMed Web of Science ®Google Scholar
• Cao J, Zhang J, Peng W, et al. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, −2, and −3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(2):259–269. doi:10.1007/s00280-016-3089-427299749
   PubMed Web of Science ®Google Scholar
• Zhou S, Shao F, Xu Z, et al. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers. Cancer Chemother Pharmacol. 2017;80(3):563–573. doi:10.1007/s00280-017-3394-628730290
   PubMed Web of Science ®Google Scholar
• Xu RH, Li J, Bai Y, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017;10(1):22.28103904
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319(24):2486–2496.29946728
   PubMed Web of Science ®Google Scholar
• Do K, Cao L, Kang Z, et al. A phase II study of sorafenib combined with cetuximab in EGFR-expressing, KRAS-mutated metastatic colorectal cancer. Clin Colorectal Cancer. 2015;14(3):154–161.25861837
   PubMed Web of Science ®Google Scholar
• Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol. 2013;31(10):1341–1347. doi:10.1200/JCO.2012.45.193023358972
   PubMed Web of Science ®Google Scholar
• Hecht JR, Trarbach T, Hainsworth JD, et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29(15):1997–2003. doi:10.1200/JCO.2010.29.449621464406
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Bajetta E, Valle J, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29(15):2004–2010.21464401
   PubMed Web of Science ®Google Scholar
• Siu LL, Shapiro JD, Jonker DJ, et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol. 2013;31(19):2477–2484. doi:10.1200/JCO.2013.49.021923690424
   PubMed Web of Science ®Google Scholar
• Hoff PM, Hochhaus A, Pestalozzi BC, et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol. 2012;30(29):3596–3603.22965965
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012;30(29):3588–3595. doi:10.1200/JCO.2012.42.535522965961
   PubMed Web of Science ®Google Scholar
• O’Neil BH, Cainap C, Van Cutsem E, et al. Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. Clin Colorectal Cancer. 2014;13(3):156–163. doi:10.1016/j.clcc.2014.04.00125066269
   PubMed Web of Science ®Google Scholar
• Chan E, Goff LW, Cardin DB, et al. Phase II study of the multikinase inhibitor of angiogenesis, linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Invest New Drugs. 2017;35(4):491–498. doi:10.1007/s10637-017-0458-828353122
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Yoshino T, Lenz HJ, et al. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Ann Oncol. 2018;29(9):1955–1963. doi:10.1093/annonc/mdx80730010751
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd, Kiss I, Bridgewater J, et al. BATON-CRC: a phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer. Clin Cancer Res. 2016;22(20):5058–5067. doi:10.1158/1078-0432.CCR-16-019027401244
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.23177514
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–629. doi:10.1016/S1470-2045(15)70156-725981818
   PubMed Web of Science ®Google Scholar
• Xie C, Zhou J, Guo Z, et al. Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013;168(7):1687–1706. doi:10.1111/bph.1204723126373
   PubMed Web of Science ®Google Scholar
• Chen Q, Tang L, Liu N, et al. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation study. Cancer Commun. 2018;38(1):66.
   Google Scholar
• Xu RH, Shen L, Wang KM, et al. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chin J Cancer. 2017;36(1):97.29273089
   PubMedGoogle Scholar
• Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24):5474–5483. doi:10.1200/JCO.2005.04.19216027439
   PubMed Web of Science ®Google Scholar
• Bellesoeur A, Carton E, Alexandre J, Goldwasser F, Huillard O. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:2801–2811. doi:10.2147/DDDT.S109640
   PubMed Web of Science ®Google Scholar
• Grávalos C, Carrato A, Tobeña M, et al. A randomized phase II study of axitinib as maintenance therapy after first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(2):e323–e329.29551560
   PubMed Web of Science ®Google Scholar
• Bendell JC, Joseph M, Barnes K, et al. A phase-2 trial of single agent axitinib as maintenance therapy following first-line treatment with modified FOLFOX/bevacizumab in patients with metastatic colorectal cancer. Cancer Invest. 2017;35(6):386–392. doi:10.1080/07357907.2017.131022128426267
   PubMed Web of Science ®Google Scholar
• Zhao D, Hou H, Zhang X. Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther. 2018;11:4137–4147. doi:10.2147/OTT.S17230530050305
   PubMed Web of Science ®Google Scholar
• Chen X, Qiu T, Zhu Y, et al. A single-arm, phase II study of apatinib in refractory metastatic colorectal cancer. Oncologist. Epub 2019 Mar 15.
   Web of Science ®Google Scholar
• Lu S, Chang J, Liu X, et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous Non‒Small-Cell lung cancer. J Clin Oncol. 2018;36(12):1207–1217. doi:10.1200/JCO.2017.76.714529528793
   PubMed Web of Science ®Google Scholar
• Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol. 2017;12(5):599–610. doi:10.1007/s11523-017-0518-128801849
   PubMed Web of Science ®Google Scholar
• Fernández Montes A, Martínez Lago N, Covela Rúa M, et al. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: prognostic and predictive markers. Cancer Med. 2019;8(3):882–889. doi:10.1002/cam4.190330690930
   PubMed Web of Science ®Google Scholar
• Noguerido A, Mulet-Margalef N, Matos I, et al. The safety of ramucirumab for the treatment of colorectal cancer. Expert Opin Drug Saf. 2018;17(9):945–951. doi:10.1080/14740338.2018.150676230073902
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Kim R, Kim TW, et al. Third- or later-line therapy for metastatic colorectal cancer: reviewing best practice. Clin Colorectal Cancer. 2019;18(1):e117–e129. doi:10.1016/j.clcc.2018.11.00230598357
   PubMed Web of Science ®Google Scholar
• Cohen R, Pellat A, Boussion H, et al. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. Bull Cancer. 2019;106(2):137–142. doi:10.1016/j.bulcan.2018.09.00430327191
   PubMed Web of Science ®Google Scholar
• Mehrvarz Sarshekeh A, Overman MJ, Kopetz S. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol. 2018;14(18):1869–1874. doi:10.2217/fon-2017-069629473436
   PubMed Web of Science ®Google Scholar
• Marginean EC, Melosky B. Is there a role for programmed death ligand-1 testing and immunotherapy in colorectal cancer with microsatellite instability? Part II-the challenge of programmed death ligand-1 testing and its role in microsatellite instability-high colorectal cancer. Arch Pathol Lab Med. 2018;142(1):26–34. doi:10.5858/arpa.2017-0041-RA29120224
   PubMed Web of Science ®Google Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. doi:10.1186/s13045-018-0664-730231931
   PubMed Web of Science ®Google Scholar
• Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H. Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Sci. 2019;110(4):1148–1155. doi:10.1111/cas.2019.110.issue-430742729
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang J, Meng Z, et al. CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer: analysis on ALTER-0303 study. Cancer Med. Epub 2018 Jun 1.
   Web of Science ®Google Scholar